Paroxetine 12.5 mg Tablet (Parowise-12.5)
Paroxetine 12.5 mg Tablets — Starting SSRI Dose
| Composition | Paroxetine 12.5 mg |
|---|---|
| Dosage Form | Tablet |
| Pack Type | Alu-Alu Blister |
| Pack Size | 10 x 10 Tablets |
| MRP | ₹ 1550 |
| Therapy | Psychiatry — SSRI (Starting Dose) |
| Storage | Store below 30 °C in a dry place, protected from light and moisture. |
WhatsApp EnquiryCall: +919041677932
For chemists, distributors and doctors: Parowise-12.5 (paroxetine 12.5 mg tablet) is available from Trumac Healthcare on a PCD franchise with monopoly rights for your district, and as wholesale stock for licensed distributors. No franchise fee; first order from ₹25,000 – work out your margin with the PTR / PTS calculator.
Buying this composition for PCD franchise, wholesale or under your own brand? See Paroxetine 12.5 mg Tablet – manufacturer, supplier & PCD franchise for available packs and brand options.
About Parowise-12.5 Tablet
Parowise-12.5 Tablet contains Paroxetine 12.5 mg — the starting dose for elderly, anxiety-sensitive patients, or initial titration of Paroxetine therapy. Slower titration reduces initial GI side effects.
Made for Trumac Healthcare at WHO-GMP certified partner units. Available for monopoly-based PCD pharma franchise and third-party manufacturing.
Looking up another Trumac medicine? See what every Trumac Healthcare brand is used for – A–Z in English and Hindi: Trumac Healthcare tablet uses. Take medicines only as your doctor prescribes.
Indications
- Initial titration in depression
- Elderly with depression/anxiety
- Anxiety-sensitive patients
- PMDD initial dose
Mechanism of Action
Paroxetine is an SSRI antidepressant — selectively inhibits presynaptic serotonin reuptake (SERT). Also has mild anticholinergic and noradrenergic reuptake inhibition. Effective in depression, anxiety disorders, PMDD, OCD, PTSD. Highest discontinuation symptoms among SSRIs due to short half-life and active metabolites.
Dosage & Administration
Adults: 12.5 mg once daily in morning, titrate up.
Side Effects
Nausea, sexual dysfunction (most common SSRI), weight gain, discontinuation syndrome (significant), drowsiness, dry mouth (anticholinergic).
Contraindications & Precautions
MAO inhibitor use (within 14 days), pregnancy (cardiac malformations — Category D), thioridazine, severe hepatic impairment.
Storage
Store below 30 °C in a dry place, protected from light and moisture.
Part of our PCD pharma franchise range, available on a monopoly basis – see the neuro psychiatry PCD franchise product list (PDF). See our full tablets PCD pharma franchise. Comparing companies? See the list of neuro PCD companies. No franchise fee; minimum first order ₹25,000 – cost and documents.
Parowise-12.5 Tablet is available for monopoly-based PCD pharma franchise across India and for third-party manufacturing under your brand. WHO-GMP certified, with full visual-aid and promotional support. Become a Trumac franchise partner →
Frequently Asked Questions
What is Parowise-12.5 Tablet used for?
Parowise-12.5 Tablet contains Paroxetine 12.5 mg. Used as per the indications described above.
How should Parowise-12.5 Tablet be taken?
As directed by your physician. Complete the prescribed course.
Is Parowise-12.5 Tablet available for PCD pharma franchise?
Yes, Trumac Healthcare offers Parowise-12.5 Tablet on monopoly-based PCD pharma franchise and for third-party manufacturing.
How should Parowise-12.5 Tablet be stored?
Store below 30 °C in a dry place, protected from light and moisture.
Is Parowise-12.5 Tablet WHO-GMP certified?
Yes, manufactured in WHO-GMP and DCGI-compliant facilities.
Related Products
- Parowise-25 Tablet — Paroxetine 25 mg
- Parowise-37.5 PR Tablet — Paroxetine 37.5 mg (Prolonged Release)
